DDInter1635 DDInter1476
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994.
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3† ,5†-adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Pirbuterol
Salmeterol {u} may lead to a major life threatening interaction when taken with {v} Nadolol
Nadolol {u} (Compound) resembles {v} (Compound) Pirbuterol
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Epinephrine {u} (Compound) resembles {v} (Compound) Pirbuterol
Salmeterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Pirbuterol
Salmeterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Pirbuterol
Salmeterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Pirbuterol
Salmeterol {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Pirbuterol
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Pirbuterol
Salmeterol {u} may lead to a major life threatening interaction when taken with {v} Nadolol
Nadolol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Pirbuterol
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Epinephrine {u} (Compound) resembles {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Pirbuterol
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) resembles Pirbuterol (Compound)
Salmeterol may lead to a major life threatening interaction when taken with Nadolol and Nadolol (Compound) resembles Pirbuterol (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) resembles Pirbuterol (Compound)
Salmeterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Pirbuterol (Compound)
Salmeterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Pirbuterol (Compound)
Salmeterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Pirbuterol (Compound)
Salmeterol (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Pirbuterol (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Pirbuterol (Compound)
Salmeterol may lead to a major life threatening interaction when taken with Nadolol and Nadolol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Pirbuterol (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) resembles Terbutaline (Compound) and Terbutaline (Compound) resembles Pirbuterol (Compound)